Poplar Therapeutics

Private

Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.poplartx.com/

Last Round

Series A

Extension

Mar 3, 2026

Total Funding Raised

$140M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunologyantibody therapybiotechatopic diseaseanti-IgEdrug discoveryclinical trialsfood allergyallergic asthmaatopic dermatitisbiopharmabiologicIgEtherapeutic candidate

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Poplar Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Poplar Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Poplar Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A Extension	Mar 3, 2026
Series A	Jan 8, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Vicki Eatwell

Chief Financial Officer

Executive Team

Poplar Therapeutics Investors

Notable investors and investment history

Poplar Therapeutics investors
Investor	Rounds
Janus Henderson Group	Series A, Series A Extension
RA Capital Management	Series A, Series A Extension
Vida Ventures	Series A Extension, Series A
ArrowMark Partners	Series A, Series A Extension
Platanus Ventures	Series A
SR One	Series A Extension, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jan 8, 2026
$50M Series A round completed.

View all signals

Poplar Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Poplar Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersCambridge, Massachusetts

Year Founded2024

Last FundingMar 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.